



# Chemical inhibitors of the conserved bacterial transcriptional regulator DksA1 suppressed quorum sensing-mediated virulence of *Pseudomonas aeruginosa*

Received for publication, December 18, 2020, and in revised form, March 16, 2021. Published, Papers in Press, March 21, 2021, <https://doi.org/10.1016/j.jbc.2021.100576>

Kyung Bae Min<sup>1,2</sup>, Wontae Hwang<sup>1,2</sup>, Kang-Mu Lee<sup>1</sup>, June Beom Kim<sup>1,2</sup>, and Sang Sun Yoon<sup>1,2,3,4,\*</sup>

From the <sup>1</sup>Department of Microbiology and Immunology, <sup>2</sup>Brain Korea 21 PLUS Project for Medical Sciences, <sup>3</sup>Institute for Immunology and Immunological Diseases, <sup>4</sup>Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea

Edited by Chris Whitfield

*Pseudomonas aeruginosa* is a Gram-negative opportunistic pathogen whose virulence is dependent on quorum sensing (QS). DksA1, an RNA polymerase-binding transcriptional regulator, plays a role in determining a number of phenotypes, including QS-mediated virulence. We therefore envisioned that DksA1 inhibitors may help to control *P. aeruginosa* infection. Here, we screened a library of 6970 chemical compounds and identified two compounds (henceforth termed Dkstatins) that specifically suppressed DksA1 activity. Treatment with these two compounds also substantially decreased the production of elastase and pyocyanin, dominant virulence determinants of *P. aeruginosa*, and protected murine hosts from lethal infection from a prototype strain of *P. aeruginosa*, PAO1. The Dkstatins also suppressed production of homoserine lactone (HSL)-based autoinducers that activate *P. aeruginosa* QS. The level of 3-oxo-C12-HSL produced by Dkstatin-treated wildtype PAO1 closely resembled that of the  $\Delta$ *dksA1* mutant. RNA-Seq analysis showed that transcription levels of QS- and virulence-associated genes were markedly reduced in Dkstatin-treated PAO1 cells, indicating that Dkstatin-mediated suppression occurs at the transcriptional level. Importantly, Dkstatins increased the antibiotic susceptibilities of PAO1, particularly to protein synthesis inhibitors, such as tobramycin and tetracycline. Co-immunoprecipitation assays demonstrated that these Dkstatins interfered with DksA1 binding to the  $\beta$  subunit of RNA polymerase, pointing to a potential mechanism of action. Collectively, our results illustrate that inhibition of *P. aeruginosa* QS may be achieved via DksA1 inhibitors and that Dkstatins may serve as potential lead compounds to control infection.

*Pseudomonas aeruginosa*, an opportunistic human pathogen, has extensive metabolic capabilities of adapting to diverse environments including immunocompromised human hosts (1). In addition, *P. aeruginosa* commonly contains high proportions of regulatory genes, particularly those for diverse signal pathways that establish resistant phenotypes (1, 2).

Stringent response (SR) is a highly conserved mechanism across bacterial species, activated in response to nutrient starvation (3). SR is mediated by two key elements, nucleotide alarmones called guanosine tetra- and penta-phosphate, (p) ppGpp, and a transcriptional regulator DksA (4, 5). DksA is a 17 kDa protein with a coiled-coil N-terminal domain and globular C-terminal domain consisting of a Zn<sup>2+</sup>-binding motif with  $\alpha$ -helix structures (3, 6). According to the structural analysis, the Zn<sup>2+</sup>-binding motif of DksA consists of four cysteine residues, which play a key role in sustaining the folding of the C-terminal and coiled-coil regions of DksA (7). Under nutrient starvation, a RelA enzyme is introduced to tRNA for the purpose of sensing amino acid deficiency and initiating the synthesis of (p)ppGpp via GTP and GDP consumption (5, 8). Using (p)ppGpp, DksA binds to RNA polymerase (RNAP) for downstream transcriptional regulation, such as the repression of rRNA gene transcription (3, 5, 9).

The mode of action regarding the interaction of DksA with RNAP was uncovered in a series of studies using *Escherichia coli*. In *E. coli*, the intracellular level of DksA remains constant throughout the life cycle, unlike (p)ppGpp (10). The constant level of DksA was initially considered to be crucial as it was identified to suppress *dnaK* mutation with its chaperon activity (3, 10). However, DksA was later revealed to be even more significant as it serves as a transcriptional suppressor of rRNA and ribosomal proteins in *E. coli* (3, 8). DksA directly binds to RNAP and modulates RNAP activity by destabilizing the open complex to prevent intermediate complexation by competition for transcription initiation (3, 4, 11). A current model demonstrates that DksA binding requires multiple interactions with (i) rim helices of the  $\beta'$ -subunit, (ii) an active site of the  $\beta$ -subunit, and (iii) a  $\beta$ -subunit site insertion 1 ( $\beta$ -SII1) in a secondary channel of RNAP (11).

DksA is also critically involved in regulating bacterial pathogenesis in several pathogens (10, 12–15). In *Vibrio cholerae*, DksA upregulated expression of *fliA*, encoding a sigma factor that regulates its motility. Furthermore, uninterrupted production of cholera toxin and hemagglutinin protease required functional DksA (16). Likewise, in *Salmonella*, DksA was found essential for the expression of motility,

\* For correspondence: Sang Sun Yoon, [sangsun\\_yoon@yuhs.ac](mailto:sangsun_yoon@yuhs.ac).

## Dkstatin-induced virulence attenuation of *P. aeruginosa*

biofilm formation, cellular invasion, and intestinal colonization that caused *in vivo* systemic infection (17). Moreover, DksA in *Salmonella* controlled central metabolism to balance its redox state, which in turn helped resist against oxidative stress produced by antimicrobial phagocytes (18).

*P. aeruginosa* harbors five genes in its genome encoding proteins belonging to the DksA superfamily, including two that are highly homologous to the typical DksA in *E. coli* (12, 19). Of these two DksA homologs, named DksA1 and DksA2, DksA1 is structurally and functionally similar to *E. coli* DksA. DksA2, on the other hand, was reported to only partially replace DksA1 functions, as it lacks the typical Zn<sup>2+</sup>-binding motif present in DksA (19). However, our recent study clearly suggested that DksA1, not DksA2, plays a dominant role as a suppressor of ribosomal gene expression (13). Importantly, a  $\Delta dksA2$  mutant exhibited almost identical phenotypes with its parental strain, PAO1, indicating that DksA2 can be dispensable. Beyond its traditional function, DksA1 was also identified to regulate a wide range of phenotypes including quorum sensing (QS)-related virulence, anaerobiosis, and motilities (13). Based upon these findings, we hypothesized that DksA1 may be an efficient target for inhibiting *P. aeruginosa* infection.

In the present work, we screened a library of chemical compounds (n = 6970) and identified two molecules that effectively compromised DksA1 activity. PAO1 cells treated with each candidate compound shared much of the characteristics of the  $\Delta dksA1$  mutant, such as significant attenuation of QS-mediated virulence and elevated antibiotic susceptibility. Furthermore, QS is considered as an antivirulence target to control *P. aeruginosa* infection in Cystic Fibrosis (CF) (20). Given that QS machinery has been a target for inhibition, our results demonstrate that DksA1 can serve as a novel avenue to achieve *P. aeruginosa* QS inhibition.

### Results

#### Screening a library of chemical compounds for DksA1 inhibitors


To set up a screening scheme in a high-throughput manner, we needed to find a phenotype of the  $\Delta dksA1$  mutant that can be easily and reproducibly measured. In *Salmonella*, it was reported that DksA modulates the redox balance in response to oxidative stress, and the NADH level decreased when the *dksA* gene is disrupted (18). We therefore examined whether the phenotype observed in *Salmonella* is also detected in *P. aeruginosa*. NADH levels are indirectly represented by the conversion of tetrazolium salt to formazan (purple pigment), which is mediated by a NADH-dependent reductase (21). In accordance with what was observed in *Salmonella*, the *P. aeruginosa*  $\Delta dksA1$  mutant produced a noticeably reduced amount of formazan (Fig. S1A). Since the formazan assay can easily be performed, we concluded that this assay can serve as an efficient screening platform, minimizing the chance of plate-to-plate variations. The library that we used was a compound library consisting of a total of 6970 chemicals that was provided by the Korean Chemical Bank. The screening was conducted in two stages. To begin with, we screened the

entire library for the formazan assay to isolate candidate compounds. Then, we compared phenotypes induced in PAO1 by each candidate compound with those of the  $\Delta dksA1$  mutant (Fig. S1B). Our goal was to isolate compounds that make PAO1 behave like the  $\Delta dksA1$  mutant. In the first step, we screened out a total of 178 chemical compounds including 25 compounds that robustly reduced formazan production and 153 mild reducers. In a repetitive formazan assay using these 153 mild reducers, we selected another set of 25 compounds that exhibited relatively strong activities in reducing formazan production. Consequently, a total of 50 compounds were selected in the first stage (Fig. S1B).

It was previously reported that transcription of genes encoding ribosomal proteins is highly activated in the  $\Delta dksA1$  mutant (12, 13). We postulated that these marked changes at the transcriptional levels may allow us to verify the phenotypes induced by candidate compounds. We therefore constructed a reporter *P. aeruginosa* strain by chromosomally integrating an *rpsB* gene promoter fused with *lacZ* ORF ( $P_{rpsB}::lacZ$ ). The *rpsB* gene codes for 30S ribosomal protein S2. In our previous work, we also reported that the production of elastase, a dominant virulence determinant and an easily measurable phenotype, is highly suppressed in the  $\Delta dksA1$  mutant (13). Therefore, we also assessed elastase production as a second-stage verification. By successive  $\beta$ -galactosidase and elastase activity assays, we finally nominated a total of four chemicals, 55B05, 02G09, 86B09, and 45G08, as a set of final candidates. We then monitored these two phenotypes in diverse cultivation conditions and at different time points to finally select chemicals that yield consistent results. While reduced elastase production and elevated *rpsB* transcription were observed at 4 h postinoculation by all four chemicals at a 50  $\mu$ M concentration, the effects of 02G09 and 45G08 did not last for the extended period of incubation (Fig. S2, A and B). At 8 h postinoculation, the levels of elastase produced in 02G09- or 45G08-treated PAO1 were almost identical to that of PAO1 (Fig. S2B). Thus, 55B05 and 86B09 were finally selected as DksA1 inhibitors, and we referred to these as Dkstatin-1 (DKST-1) and Dkstatin-2 (DKST-2).

#### Structure and specificity of Dkstatin-1 (DKST-1) and Dkstatin-2 (DKST-2)

The Korean Chemical Bank database provides the structures of DKST-1 and DKST-2, and they were found to have distinct chemical structures (Fig. 1, A and B). To further confirm that Dkstatin (DKST) molecules act specifically against DksA1 activity, formazan production and *rpsB* reporter expression were measured in PAO1 and the  $\Delta dksA1$  mutant as well. Hereafter, DKST-1 and -2 were used at 150  $\mu$ M concentrations in all experiments. Again, levels of formazan production in PAO1 were noticeably reduced in the presence of DKST treatment (Fig. 1C). It is of interest that formazan production in PAO1 treated with 150  $\mu$ M DKST-1 was even lower than that of the  $\Delta dksA1$  mutant. On the other hand, levels of formazan production in the  $\Delta dksA1$  mutant were not further decreased by either DKST compound (Fig. 1C). Likewise, DKST-1 and DKST-2 did not further increase



**Figure 1. Effect of Dkstatin candidate compounds on *P. aeruginosa*.** A and B, chemical structure of Dkstatin-1 (DKST-1) and Dkstatin-2 (DKST-2). C, relative formazan production of PAO1 and  $\Delta dksA1$  mutant grown in LB with 150  $\mu$ M DKST-1 and DKST-2 for 4 h. The values of mean  $\pm$  S.D. are presented (n = 3). D, relative *rpsB* expression of PAO1  $P_{rpsB}::lacZ$  and  $\Delta dksA1$   $P_{rpsB}::lacZ$  strains incubated in LB with 150  $\mu$ M DKST-1 and DKST-2 for 8 h. The *rpsB* gene expression is represented as  $\beta$ -galactosidase activity. The values of mean  $\pm$  S.D. are presented (n = 3).

the *rpsB* gene transcription in the  $\Delta dksA1$  mutant (Fig. 1D). As DKST-1 and DKST-2 were identified to inhibit DksA1 activity, no apparent effects of DKSTs were present in a strain devoid of *dksA1* gene. These results suggest that Dkstatin compounds selectively inhibit DksA1 activity.

#### DKST compounds interrupt QS-mediated virulence in *P. aeruginosa*


DksA1 plays versatile roles at the transcriptional level affecting various phenotypes (13). Therefore, DKST molecules inhibiting the activity of DksA1 may induce diverse physiological changes in *P. aeruginosa*. To identify whether DKSTs affect the growth of PAO1, we conducted growth curve experiments of PAO1 in the presence of 150  $\mu$ M of DKSTs. Control growth curves were obtained by adding equal volume of DMSO used as a solvent. In comparison with PAO1 and  $\Delta dksA1$  mutant, PAO1 growth never changed upon DKST-1 supplementation (Fig. 2A). To our surprise, a noticeable increase CFU/ml values in PAO1 growth was repeatedly observed at exponential phase when treated with DKST-2 (Fig. 2A). When CFU was enumerated 8 h postinoculation, no obvious growth enhancement was observed (Fig. 2B).

Together, these two sets of results indicate that DKST-1 and -2 at least do not downregulate bacterial growth and viability.

At a concentration of 150  $\mu$ M, DKST-2 suppressed elastase production to a more significant degree (Fig. 2C). Under DKST-2-treated conditions, the level of elastase production was less than 40% of what control PAO1 cells produced. Elastase production in PAO1 treated with 150  $\mu$ M DKST-1 was approximately 65% of the control level. Along with elastase, pyocyanin is another crucial virulence determinant whose production is also controlled by QS in *P. aeruginosa* (2, 22, 23). When we measured the pyocyanin production, a marked reduction was observed in DKST-treated PAO1 (Fig. 2D). Interestingly, the degree of reduction by either DKST molecule in PAO1 was comparable to that induced by the *dksA1* gene deletion (Fig. 2D). The loss of pyocyanin production was clearly represented in the image of culture supernatants shown in Figure 2E.

In *P. aeruginosa*, QS is operated by small organic molecules, termed autoinducers (24). Since major QS-mediated phenotypes were suppressed in DKST-treated PAO1 and in the  $\Delta dksA1$  mutant, we monitored how many autoinducers were produced in response to the DKST treatment. Two homoserine lactone (HSL) autoinducers, 3-oxo-C12-HSL and

## Dkstatin-induced virulence attenuation of *P. aeruginosa*



**Figure 2. Effects of Dkstatin-1 and Dkstatin-2 on bacterial growth and virulence.** A, growth curves of PAO1 and  $\Delta dksA1$  mutant in plain LB and LB supplemented with 150  $\mu$ M of Dkstatin-1 (DKST-1) or Dkstatin-2 (DKST-2). Aliquots of bacterial cultures ( $n = 3$ ) were withdrawn every hour to measure CFU/ml values. \* $p < 0.05$  versus growth of PAO1. B, cell viability of PAO1 incubated with DKST-1 and DKST-2. C, relative elastase activity of tested strains. Elastase activity was measured as described in the [Experimental procedure](#) and was normalized with that of PAO1. The values of mean  $\pm$  S.D. are presented ( $n = 4$ ). \* $p < 0.05$  versus that produced of PAO1. \*\* $p < 0.05$  versus that produced of PAO1-treated with DKST-1. D, pyocyanin production in each condition was quantified and normalized with that of PAO1. The values of mean  $\pm$  S.D. are presented ( $n = 3$ ). \* $p < 0.05$  versus that produced of PAO1. E, visual comparison of bacterial culture supernatants. Loss of pigment was clearly observed in PAO1 and both Dkstatin compounds. Statistical analysis in all experiments was carried out for paired Student's *t*-test in comparison of PAO1 as control group.


C4-HSL, were semiquantitatively measured as described in the Methods section. Based on our quantification, levels of 3-oxo-C12-HSL produced in either DKST-1 or DKST-2-treated PAO1 cells were almost identical to that in the  $\Delta dksA1$  mutant (Fig. 3A). Similarly, levels of C4-HSL produced upon treatment with either DKST were noticeably decreased to 53% and 63% of what was detected in the control group, respectively (Fig. 3B).

When DKST-treated PAO1 cells were cotreated with extraneous C4-HSL and 3-oxo-C12-HSL, elastase production was restored (Fig. S3). Elastase production was almost completely recovered following 4 h autoinducer complementation, while the complementation effects diminished thereafter (Fig. S3). These results demonstrate that the LasI-R and RhlI-R QS circuits can be substantially impaired by two DKSTs, with the LasI-R system being suppressed almost to the degree of the  $\Delta dksA1$  mutant. Furthermore, our results indicate that DKST-induced virulence attenuation occurred at the level of the HSL-based autoinducer production.

### Anaerobic respiration is affected by DKSTs

The transcription of genes involved in denitrification or anaerobic respiration requires DksA1 activity (13). We

therefore examined whether the DKST compounds also have an impact on anaerobic respiratory growth of *P. aeruginosa*. We tested bacterial growth using  $\text{NO}_3^-$  as an alternative electron acceptor. When cells were grown anaerobically with 25 mM  $\text{NO}_3^-$ , PAO1 strains reached an average  $\text{OD}_{600}$  value of  $\sim 1.6$  in 24 h (Fig. 4A). In contrast, final  $\text{OD}_{600}$  values plateaued at  $\sim 1.24$  in the  $\Delta dksA1$  mutant under the same conditions. Under the DKST-1 supplemented growth conditions, PAO1 grew up to  $\text{OD}_{600}$  values of  $\sim 1.18$ , similar to the growth of a  $\Delta dksA1$  mutant. Likewise, average  $\text{OD}_{600}$  values were  $\sim 1.27$  in the presence of DKST-2 (Fig. 4A). Interestingly, the growth stimulating effect of DKST-2 (Fig. 2A) observed during aerobic growth was not detected under anaerobic respiration. In a CFU counting assay, we observed that the addition of DKST-2 resulted in a similar outcome as the  $\Delta dksA1$  mutant (Fig. 4B). Around tenfold decreases in viable cell numbers were observed at the end of the growth experiments both in PAO1 treated with DKST-2 and in the  $\Delta dksA1$  mutant, whereas a significant difference in cell numbers was not detected when DKST-1 was supplemented. Together, these results illustrate that DKST compounds are involved in suppression of major anaerobic respiration pathways in



**Figure 3. Measurement of 3-oxo-C12-HSL and C4-HSL produced when supplemented with Dkstatin compounds.** A, relative levels of 3-oxo-C12-HSL (C12-HSL) were measured using an *E. coli* reporter strain harboring a pKDT17 plasmid. Concentrations of C12-HSL are represented as  $\beta$ -galactosidase activity. The values of mean  $\pm$  S.D. are presented (n = 3). B, relative levels of *N*-butyryl-homoserine lactone (C4-HSL) were monitored by measuring the violacein production from the biosensor strain *C. violaceum* CV026. Violaicin production was measured at 590 nm absorbance and was normalized to the OD<sub>600</sub> values of CV026. In total, 150  $\mu$ M Dkstatin-1 (DKST-1) and DKST-2 (DKST-2) were supplemented in all experiments.

*P. aeruginosa*, although the degree of impact varies between the two DKSTs.


#### DKST-1 and DKST-2 increase antibiotic susceptibility

*P. aeruginosa* is notorious for its antibiotic resistance (1). As an opportunistic pathogen, it has also acquired resistance to multiple drugs (1, 25). Our previous data showed that the  $\Delta dksA1$  mutant became hypersusceptible to gentamycin or tetracycline at sub-MIC conditions (13). In contrast, the mutant was not more susceptible to  $\beta$ -lactam antibiotics, such as ampicillin and carbenicillin, than PAO1 (13). To examine whether the DKST treatment would lead to the interruption of

DksA1 activity resulting in increased antibiotic susceptibility, we tested imipenem (Imp), gentamycin (GM), tetracycline (TC), kanamycin (KM), streptomycin (SM), and tobramycin (TB). DKSTs failed to increase PAO1 susceptibility in response to the treatment with Imp at a 2.5  $\mu$ g/ml concentration (Fig. 5A). Supplementation of DKST-1 or DKST-2 both at 150  $\mu$ M concentration significantly reduced cell viability when PAO1 cells were incubated with 2.5  $\mu$ g/ml of GM (Fig. 5B). Here, a more than tenfold decrease in cell viability was detected in the presence of either DKST. Interestingly, increased susceptibility by DKST was also observed during incubation with other aminoglycoside antibiotics such as KM (Fig. 5D), SM (Fig. 5E) or TB (Fig. 5F). In the presence of DKST, viable cell numbers of KM-treated PAO1 cells decreased around tenfold when compared with the DMSO-treated PAO1 control (Fig. 5D). Severe loss of viability was observed in PAO1 cells being cotreated with SM and DKST as well (Fig. 5E). We also observed that DKST treatment increased PAO1's susceptibility to 8  $\mu$ g/ml of TC, an antibiotic that also inhibits protein synthesis machinery (Fig. 5C). These results indicate that DKSTs specifically increase bacterial susceptibilities to antibiotics that specifically target protein biosynthesis in *P. aeruginosa*.


#### DKSTs interfere with DksA1's interaction with RNA polymerase

Action of DksA1 is dependent on its interaction with RNA polymerase (RNAP). It was reported that DksA1 binds to the  $\beta$  subunit of RNAP in *E. coli* (11). We hypothesized that DKSTs may work by one of two possible scenarios. First, DKSTs may inhibit the production of DksA1 in *P. aeruginosa*. Second, DKSTs may interfere with DksA1's binding to RNAP. To precisely understand how DKSTs inhibit DksA1 activity, we constructed a modified PAO1 strain, where the 3'-end of the *dksA1* gene is fused with the nucleotide sequences coding for the 3XFLAG tag. In this strain, DksA1 is translated as a fusion protein with the 3XFLAG tag at its C-terminus. To begin with, we tested whether DKST compounds affect production of DksA1 through western blotting. As a result, western blotting



**Figure 4. Effects of Dkstatin-1 and Dkstatin-2 on anaerobic respiration.** A, growth curves of PAO1 and  $\Delta dksA1$  mutant in LB and LB supplemented with 150  $\mu$ M Dkstatin-1 (DKST-1) and Dkstatin-2 (DKST-2). In total, 25 mM  $\text{NO}_3^-$  was added as an alternative electron receptor. OD values of bacterial culture aliquots (n = 2) were measured every 2 h. B, the cell viability of anaerobically grown  $\Delta dksA1$  mutant and PAO1 incubated with 150  $\mu$ M DKST-1 and DKST-2. Bacterial cultures grown anaerobically for 24 h in LB supplemented with 25 mM  $\text{NO}_3^-$  were serially diluted. In total, 10  $\mu$ l of each diluent was spot inoculated on an LB agar plate. The plates were incubated in anaerobic conditions at 37  $^\circ\text{C}$  for 24 h.

## Dkstatin-induced virulence attenuation of *P. aeruginosa*



**Figure 5. Effects of Dkstatin-1 and Dkstatin-2 on antibiotic susceptibility.** CFU counting of PAO1 incubated with Dkstatin-1 (DKST-1) and Dkstatin-2 (DKST-2) when supplemented with antibiotics; (A) 2.5  $\mu\text{g/ml}$  of imipenem, (B) 2.5  $\mu\text{g/ml}$  of gentamicin, (C) 8  $\mu\text{g/ml}$  of tetracycline, (D) 25  $\mu\text{g/ml}$  of kanamycin, (E) 12.5  $\mu\text{g/ml}$  of streptomycin, and (F) 1  $\mu\text{g/ml}$  of tobramycin.  $\Delta dksA1$  mutant was incubated in LB under same condition to PAO1. All experiments were performed as three independent replicates.


using an anti-FLAG antibody indicates that the level of DksA1 production was never changed by the treatment with either DKST (Fig. 6A). The DksA1-specific band was not detected in the sample prepared from the original PAO1 strain (Fig. 6A, far-left lane). Next, we conducted a co-immunoprecipitation assay using a magnetic bead (on which an anti-FLAG antibody is immobilized) to examine the effect of DKST treatment on the interaction of DksA1 with RNAP. When precipitated fractions in each preparation were probed with an anti-RpoB antibody, the RpoB band intensity was markedly reduced in both DKST-treated samples, with DKST-2 being superior to DKST-1 in conferring such effects (Fig. 6B). Taken together, these results demonstrate that DKSTs likely act as inhibitors at the posttranslational level by interfering with DksA1's binding to RNAP.

### DKST-1 and DKST-2 induced distinct changes in transcriptome profiles of PAO1

Although two DKSTs invariably suppressed the activity of DksA1, inducing similar phenotypic changes, the chemical structures of the two molecules are quite different (Fig. 1, A and B). To better understand the effects of DKST

treatment, we compared transcriptome landscapes of PAO1 grown without or with either DKST. A global view of the entire transcriptome uncovered the substantial differences between cells treated with DKST-1 or DKST-2 (Fig. S4A). This finding was also supported by our PCA plot, which indicates that either treatment induced divergent changes (Fig. S4B). As far as the number of affected genes was concerned, the effect of DKST-1 treatment appeared stronger than that exerted by DKST-2 (Fig. 7A). Again, among those genes whose expression was substantially altered, only a small portion was simultaneously affected by either compound.

At first, we confirmed that the transcription of genes encoding ribosomal proteins was upregulated during the treatment with DKST-1 or DKST-2, with the latter exhibiting more significant effects (Fig. 7B). These results further verified that two compounds can in fact effectively compromise the activity of DksA1. We then examined the effects of DKST treatment on the expression of genes involved in QS and QS-mediated virulence factor production. As shown in Figure 7C, transcription of genes encoding autoinducer synthases and autoinducer-binding receptors was suppressed in DKST-



**Figure 6. Intracellular production of DksA1 in response to Dkstatin treatment and effects of Dkstatin treatment on binding of DksA1 with RNA polymerase  $\beta$  subunit.** A, original strain of PAO1 (first lane) and PAO1 harboring a *dksA1::FLAG* translational fusion construct (following lane) were grown in LB in the presence of either 150  $\mu$ M Dkstatin-1 (DKST-1) or Dkstatin-2 (DKST-2) for 8 h. Intracellular fractions were subjected to western blot with an anti-FLAG antibody. As a control, strains were treated with equal volumes of DMSO (Con). Samples at equal protein concentrations were loaded into 12% SDS-PAGE gel. B, RpoB western blot conducted with anti-RpoB antibody to determine RpoB of *P. aeruginosa* (upper panel). RpoB and DksA1 western blot conducted with RpoB antibody and anti-FLAG antibody after immunoprecipitation using magnetic beads. RpoB western blot shown with anti-RpoB antibody from immunoprecipitation conducted by magnetic beads coated with anti-FLAG antibody (middle panel). Relative RpoB band intensities were indicated. DksA1-FLAG western blot conducted with anti-FLAG antibody using precipitates produced by magnetic beads (bottom panel). A PAO1 strain with *dksA1::FLAG* translational fusion construct was grown for 8 h in the presence of 150  $\mu$ M Dkstatin-1 (DKST-1), Dkstatin-2 (DKST-2) or an equal volume of DMSO (Con). Each intracellular extract was incubated with an equal volume of magnetic beads conjugated with an anti-FLAG antibody and was precipitated. Resuspended precipitates were loaded onto SDS-PAGE gel for western blot with the anti-FLAG antibody and the anti-RpoB antibody. IP, immunoprecipitation; WB, western blot.

treated PAO1 cells. Among these, *pqsABCDE* and *phnAB* genes that constitute the PQS biosynthesis cluster were most affected. Importantly, the expression of virulence-associated genes was remarkably decreased, especially in response to the treatment with DKST-1 (Fig. 7D). Genes coding for elastase (*lasB*), alkaline protease (*aprADEF*), and rhamnolipid (*rhlAB*) were considerably downregulated. Similarly, transcription of genes involved in phenazines production (*phzA1~G1* and *phzA2~G2*) and siderophore biosynthesis (*pchA~G* and *pchR*) were also suppressed in DKST-treated cells (Fig. 7D). These results clearly suggest that DKST-induced virulence suppression is due to the effects manifested at the transcriptional level. In addition, gene expression for the production of hydrogen cyanide (*hcnA~C*) and type II secretion machinery (*tadB~D*) was less active in the presence of DKSTs.


In our previous data shown in Figure 4A, DKST treatments suppressed anaerobic respiratory growth of PAO1. In *P. aeruginosa*, anaerobic respiration is mediated by a series of reductions from nitrate ( $\text{NO}_3^-$ ) to  $\text{N}_2$  with nitrite ( $\text{NO}_2^-$ ), nitric oxide (NO), and nitrous oxide ( $\text{N}_2\text{O}$ ) as intermediates (26). The expression of genes involved in the activity of nitrate reductase (NAR) that mediates the first step of anaerobic denitrification was slightly increased in the presence of DKSTs. In contrast, DKSTs significantly suppressed the expressions of gene clusters (*nirSMCFLGHJND* and *norCBD*) encoding nitrite reductase (NIR) and nitric oxide reductase (NOR) that catalyze the next steps of denitrification to produce nitrous oxide (27). Similarly, the expression of *nosRZDFYL* cluster encoding nitrous oxide reductase also invariably decreased during DKST treatment (Fig. 7E).

Our data shown in Figure 2A indicate that DKST-2 stimulated PAO1 growth in LB. To address this unexpected phenomenon, our interest also reached the genes involved in energy metabolism such as systems for electron transport and ATP biosynthesis. The two gene clusters, *ccoN1O1Q1P1* and *ccoN2O2Q2P2*, encode subunits of *cbb3*-type cytochrome oxidase, a critical enzyme for aerobic respiration (28, 29). Compared with the control PAO1 cells, transcription of these two gene clusters was remarkably increased in PAO1 cells treated with DKST-2 (Fig. 7F). Furthermore, a large operon *atpABCDEFGHI* encoding ATP synthase complex was more actively transcribed in the same cells (Fig. 7G). These results provided insight into how DKST-2 treatment promoted the PAO1 aerobic growth. Collectively, our RNASeq analysis revealed that two DKST compounds induced transcriptional changes, which were well reflected at the phenotypic level. In addition, we further confirmed that the wild-type PAO1 cells subjected to DKST treatment behaved like a  $\Delta$ *dksA1* mutant.

#### **DKST-1 and DKST-2 attenuated virulence of *P. aeruginosa* in vivo**

As the production of virulence factors decreased by DKST treatment, we next tested whether DKST-induced virulence attenuation is still valid *in vivo* using 8-week-old C57BL/6 female mice. All mice were intranasally infected with freshly harvested PAO1 cells ( $\sim 10^6$  CFU). Mice infected with PAO1 ( $n = 3$ ) perished within 36 h (Fig. 8A, green line). On the other hand, when either DKST was supplemented together with PAO1 infection ( $n = 4$ ), mice exhibited significantly increased survival rates and survived even after 48 h postinfection (Fig. 8A). In a separate set of experiments, we also examined the effect of DKST treatment on PAO1 proliferation inside the host airway. In this case, mice were infected with  $3 \times 10^6$  PAO1 cells. At 12 h postinfection, the average bacterial load in the lungs of the control group was  $\sim 5.2 \times 10^5$  CFU. Importantly, the bacterial load was significantly decreased to  $\sim 4.7 \times 10^4$  CFU, when treated with DKST-1. In contrast, the bacterial count was not decreased by DKST-2 (Fig. 8B). This finding correlates well with our RNASeq results, in that DKST-1 treatment strongly suppressed the transcription of virulence-associated genes (Fig. 7D). We also assessed the effects of

## Dkstatin-induced virulence attenuation of *P. aeruginosa*



**Figure 7. Comparison of effects of Dkstatin-1 and Dkstatin-2 on gene expression.** A, Venn diagram for number of genes affected by Dkstatin-1 (DKST-1) or Dkstatin-2 (DKST-2) treatment. Expression fold range was separated as two to fourfold and over fourfold. B, expression of 50S and 30S ribosomal protein encoding genes. DKST-2 was more effective to increase expression of those genes. C, expression of genes participated in three major QS circuits was downregulated in the presence of both DKST-1 and DKST-2. D, transcription of genes for virulence factors. Phenazine biosynthesis clusters (*phzA1~G1* and *phzA2~G2*) were remarkably downregulated for either DKST. E, expression of genes involved in all steps of denitrification. Gene clusters (*nirSMCFLGHJND* and *norCBD*) encoding nitrite reductase (NIR) and nitric oxide reductase (NOR) were invariably downregulated in both DKST-1 and DKST-2. F, expression of genes categorized as electro transfer. The two *cbb3*-type cytochrome c oxidase encoding gene set (*ccoN1~P1* and *ccoN2~P2*) was upregulated by DKST-2. G, expression of ATP synthase complex encoding gene operon. All total RNAs were harvested as biological duplicates.


DKST treatment by visualizing lung tissues. Intranasal infection of PAO1 led to infiltration of immune cells and a reduction of alveolar spaces, which are indicators of severe airway infections (Fig. 8F). When PAO1-infected mice were treated with DKSTs, inflammatory symptoms substantially decreased compared with those observed in the control infection group (Fig. 8, G and H versus Fig. 8F). The presence of lung damage was not obvious when the mice were treated with DKST-1 (Fig. 8D) or DKST-2 (Fig. 8E). Together, these results suggested that DKST-1 and DKST-2 are not toxic to the murine host and thereby these two molecules may have potential to be developed as anti-Pseudomonas agents for human patients.

### Discussion

Bacterial cells developed numerous systems to handle environmental stresses. SR is one of those systems, and it is activated under the stress of nutrient starvation. Active SR requires DksA1, a protein conserved across bacterial species. Besides this well-recognized function, previous studies from our lab revealed that DksA1 acts as a major transcriptional regulator for QS-mediated virulence expression in *P. aeruginosa* (13). In addition, DksA1 is also required for uninterrupted expression of genes encoding proteins for biofilm formation, motility, anaerobic respiration through denitrification, and polyamine metabolism (13). As DksA1 participates in regulating a wide range of phenotypes,

including virulence in *P. aeruginosa*, we postulated that DksA1 is an effective drug target, the inhibition of which may result in virulence attenuation, eventually leading to control of recalcitrant *P. aeruginosa* infections. The success of our compound library screen is attributed to the following aspects. First, the use of formazan production as a surrogate marker of DksA1 activity provided a system that allowed us to screen 6970 compounds with minimal error. Second, the reporter strain, in which the transcriptional fusion of  $P_{rpsB}::lacZ$  has been inserted as a single copy at a nonfunctional region of PAO1 genome (30), provided a reliable method for the second-stage verification. This was critical because reduced production of formazan can result from other metabolic alterations. Lastly, DKST-1 and DKST-2 were found to be commercially available for purchase, enabling us to test the effects of these two final candidates at higher concentrations with no limited supply. Considering that the initial screening could only be performed with compounds at 50  $\mu$ M concentration, the availability of DKSTs made this study more feasible.

DKST-1 and DKST-2 have quite different chemical structures. Both compounds, however, induced specific outcomes mediated by loss of DksA1 activity, ranging from (i) increased *rpsB* expression, (ii) reduced elastase production, (iii) reduced pyocyanin production, (iv) suppressed autoinducer production, and (v) defective anaerobic respiration. These results display the common features of two compounds affecting DksA1 activity. DksA1 possesses a  $Zn^{2+}$ -binding motif



**Figure 8.** *In vivo* virulence analyses of Dkstatin-1 and Dkstatin-2. **A**, survival curves of mice infected with PAO1 (green line) and PAO1 combined with Dkstatin-1 (DKST-1, red line) or Dkstatin-2 (DKST-2, orange line). The infection dose was  $\sim 10^6$  cells per mouse.  $*p < 0.05$  versus survival rate of PAO1-infected mice. Four mice were used in each group. **B**, bacterial CFU values counted from whole dissected lungs. The initial dose was  $3 \times 10^5$  cells per mouse of PAO1 or PAO1 combined with 150  $\mu\text{M}$  of DKST-1 or DKST-2.  $*p < 0.05$  versus CFU of the PAO1-infected mice. **C**, H&E stained histological visualizations of lung tissues from mice intranasally administered DMSO only, **(D)** 150  $\mu\text{M}$  of DKST-1 and **(E)** DKST-2. **F**, H&E stained lung tissues of mice infected with PAO1 combined with DMSO, **(G)** PAO1 combined with 150  $\mu\text{M}$  of DKST-1 and **(H)** DKST-2. 200  $\mu\text{m}$  scale bar was indicated as black bar at lower right.

(CXXC-N<sup>17</sup>-CXXC) consisting of four cysteine residues at its C-terminus, and this motif is critical for its structure and function. Of note, the cysteine thiol group is highly susceptible to oxidation by electrophilic molecules (3, 19, 31). Regardless of the structural differences, both compounds harbor reactive groups, such as fluorine (32) and butanone (33, 34). Thus, it is reasonable to hypothesize that oxidizing groups in DKSTs may affect the DksA1 structure, which in turn leads to interference with DksA1 binding to a subunit of RNAP. Future work should focus on understanding DKST-induced structural modification of DksA1 and its downstream consequences. To this end, it is necessary to explore other chemicals harboring diverse oxidizing moieties as well.

Based on Figure 2A, DKST-2 stimulated bacterial growth. While the enhanced bacterial growth was not fully reflected in the viable cell counting assay, we became interested in this unexpected result. It is counterintuitive that a compound that has potential to be developed as an anti-infective agent also stimulates bacterial growth. However, it is also noteworthy that actively replicating cells are well known to be more susceptible to antibiotic treatment (35). In line with this notion, *P. aeruginosa* invaders might be more exposed to host immunity when they multiply at a faster rate. In contrast to the

aerobic culture, DKST-2 strongly suppressed anaerobic respiratory growth of PAO1 (Fig. 4B). Earlier studies clearly suggest that *P. aeruginosa* may benefit from anaerobiosis during chronic airway infection (26). It will be important to further clarify whether DKST-2 specifically suppresses chronic airway infection by *P. aeruginosa*.

QS, a cell density-dependent gene regulatory system, is crucial for the production of virulence determinants in *P. aeruginosa* (23). Therefore, *P. aeruginosa* QS has been extensively studied as a therapeutic target for virulence attenuation (1, 23, 36). To date, strategies for QS inhibition include receptor inactivation (37), inhibition of signal synthesis, use of autoinducer analogues (38), signal degradation (39, 40), and use in combination with antibiotics (38). Flavonoids bind QS receptor, LasR, and RhIR, to reduce virulence factor production (37). N-decanoyl-L-homoserine benzyl ester, a structural analogue of 3-oxo-C12-HSL, downregulates elastase production, swarming motility, and biofilm formation without growth defects (22). This QS-inhibitor also synergistically interacts with gentamicin and tobramycin (38). Another QS inhibitor, meta-bromo-thiolactone, affects LasR and RhIR activity to decrease pyocyanin production and biofilm formation in *P. aeruginosa* PA14 strain (41). In a screen with a

## Dkstatin-induced virulence attenuation of *P. aeruginosa*

synthetic N-acyl-homoserine lactone (A-HSL) library, various HSL derivatives were found to antagonize the activity of LasR and LuxR in *P. aeruginosa* and *Vibrio fischeri* (42). Likewise, a couple of autoinducer analogues were found to antagonize TraR, a QS-related LuxR homologue in *Agrobacterium tumefaciens* (42). Of note, the previously mentioned examples show findings from studies designed to uncover molecules that directly inhibit or antagonize at various levels of the *P. aeruginosa* QS machinery. In the present study, however, we discovered molecules that target DksA1, whose involvement in *P. aeruginosa* QS is relatively a new subject. We argue that DksA1 should be an avenue for future exploration in the context of development of *P. aeruginosa* QS inhibitors with a focus on its molecular nature and its impact on virulence gene regulation.

Our RNASeq analysis clearly suggested that the two DKSTs induced distinct changes in the genome-wide transcription pattern. When differentially expressed genes (DEGs) were categorized based on the gene ontology (GO) term, a larger number of GO terms were retrieved in DKST-2-treated group (11 terms) than in the DKST-1-treated group (9 terms). Of particular interest, the most significantly presented GO term in the DKST-2 treated group was “translation” with all 23 upregulated genes (Fig. S5B). Along with this GO term, several other functional categories, such as ribosomal assembly and energy metabolism, were also identified with genes of enhanced transcription. Given that these changes resemble the characteristics of the  $\Delta dksA1$  mutant, it is likely that DKST-2, as compared with DKST-1, is more potent in inhibiting DksA1 activity. Consistent with this idea, binding of DksA1::FLAG and RpoB was hampered to a greater degree by DKST-2 (Fig. 6B). In the DKST-1-treated group, on the other hand, the “phenazines biosynthesis process” was most significantly presented (Fig. S5A). In addition, 10 out of 12 genes in the “pathogenesis” category and all genes in the “secretion,” “type VI secretion system,” and “chemotaxis” terms were downregulated in DKST-1-treated cells (Fig. S5A), suggesting that DKST-1 may be more directly engaged in attenuating *P. aeruginosa* virulence. Collectively, these additional bioinformatic analyses further support the notion that DKST-1 and DKST-2 may operate in different modes of action even though these two molecules were identified as DksA1 inhibitors.

Antibiotic resistance in many human pathogens (including *P. aeruginosa*) has already become a global healthcare problem. Against the opportunistic features of *P. aeruginosa*, we need to come up with antibiotic-independent infection control strategies. Interventions that could achieve virulence attenuation without imposing selective pressure have been actively attempted (36). DKSTs identified in the present study significantly downregulated *P. aeruginosa* virulence by suppressing QS mechanisms. Moreover, DKSTs induced elevated antibiotic efficacy at sub-MIC conditions, especially for antibiotics that inactivate protein synthesis. As DksA1 suppresses transcription of genes encoding rRNA and ribosomal proteins, macromolecular ribosomes are readily accumulated when DksA1 is inactivated. Therefore, it is anticipated that

ribosome-targeting antibiotics are more active under such conditions.

In summary, DksA1 in *P. aeruginosa* positively regulates its virulence by activating QS. This finding led us to hypothesize that inhibiting DksA1 would result in virulence attenuation of the pathogenic *P. aeruginosa*. We identified two molecules that effectively suppressed DksA1 function from a large-scale compound library screen. These two compounds suppressed *P. aeruginosa* virulence and therefore protected a murine host from lethal infection with *P. aeruginosa*. Moreover, the compounds also rendered *P. aeruginosa* more susceptible to antibiotics. Our results demonstrate that fatal *P. aeruginosa* infections can be controlled by inhibiting DksA1. Collectively, DKSTs are attractive drug candidates in establishing future plans to cope with antibiotic-resistant infections. We anticipate that future investigations will propose detailed molecular mechanisms of DKSTs and apply these in human trials.

## Experimental procedure

### Ethics statement

All animal studies were performed in compliance with the guidelines provided by the Department of Animal Resources of Yonsei Biomedical Research Institute. The Committee on the Ethics of Animal Experiments at the Yonsei University College of Medicine approved this study (permit number 2018-0246).

### Bacterial strains, culture conditions, and chemicals

Bacterial species and plasmids used in this study are listed in Table S1. A laboratory strain of *P. aeruginosa*, PAO1, was used as a wild-type strain. Unless otherwise specified, bacterial strains were cultivated in Luria-Bertani media (LB; 1% (w/v) tryptone, 0.5% (w/v) yeast extract, and 1% (w/v) sodium chloride) at 37 °C. Standard cloning procedures that involved allelic exchange were performed. When necessary, ampicillin (100 µg/ml), carbenicillin (100 µg/ml), gentamycin (60 µg/ml), or irgasan (25 µg/ml) were used for clonal selection. DNA sequences encoding 3XFLAG tag were amplified and ligated to the downstream of the multicloning site (MCS) of the pBAD24 plasmid, resulting in the construction of pBAD24F. Then, the *dksA1* gene was cloned into the MCS of pBAD24F. The resulting *dksA1*::FLAG sequence was amplified and ligated into pCVD442 (35) for chromosomal integration. The promoter region of *rpsB* gene was fused with the promoterless *lacZ* open reading frame ( $P_{rpsB}$ ::*lacZ*), and the resulting construct was cloned into the plasmid, pUC18-mini-Tn7t-Gm-*lacZ* (30) for chromosomal integration. Dkstatin-1 (4,4'-(4,4'-biphenyldiyl disulfonyl)di(2-butanone)) and Dkstatin-2 (N-ethyl-3-[(3-fluorophenyl)methoxy]-N-[(1-methyl-1H-imidazol-5-yl)methyl]aniline) were purchased from Chembridge Corp and Asinex Inc, respectively.

### Screening of chemical compounds

Screening of chemical compounds was performed in two phases. Using a chemical compound library consisting of 6970 chemicals provided by the Korea Chemical Bank (<https://chembank.org/>), we first screened for chemical

compounds that inhibit DksA1 activity. The total library was tenfold diluted with DMSO to increase the volume. A 100-fold diluted overnight culture of *P. aeruginosa* PAO1 and the  $\Delta dksA1$  mutant were then incubated in fresh media for an additional 4 h to activate the cells. The obtained OD<sub>600</sub> values of these strains were adjusted to 1.0. Then, 120  $\mu$ l of the adjusted culture was inoculated in 96-well plates that contain 50  $\mu$ M of chemical compounds, and these were incubated at 37 °C for 1 h to examine formazan production. After incubation, 0.05 mg/ml of thiazolyl blue tetrazolium bromide (Sigma-Aldrich) was distributed into each well of the test plates, and they were incubated for an additional 30 min at 37 °C. The formazan production was measured at a 550 nm wavelength after dissolving it in DMSO. The top 50 compounds that presented the lowest levels of formazan production during the first screening phase were then subjected to a subsequent screening. In the following screening phase, a reporter strain PAO1  $P_{rpsB}::lacZ$  was diluted 100-fold and added to 1.5 ml of LB supplemented with 50  $\mu$ M of each of the 50 compounds. The sample was then incubated for 4 h at 37 °C with shaking. *rpsB* expression of the reporter strain was represented in Miller Units and was measured as described previously (13). Based on the *rpsB* expression, the top 20 compounds among the 50 previously screened compounds were selected. To further narrow down the candidate compounds from the 20 selected compounds, the reporter strain was incubated in 3 ml of LB with the addition of 50  $\mu$ M of each of the 20 compounds for 4 h with shaking. Measurement of the elastase activity and quantification of *rpsB* expression allowed us to come down to the four most efficacious compounds: 55B05, 02G09, 86B09, and 45G08. Then, 50  $\mu$ M of four these compounds was tested again by measuring elastase activity and *rpsB* expression of reporter strain incubated in 5 ml of LB for 4 to 8 h at 37 °C. 55B06 and 86B09 were specifically chosen as they showed sustained effects on elastase activity and *rpsB* expression. Then, 150  $\mu$ M of 55B05 and 86B09 were each added to PAO1 and  $\Delta dksA1$  mutant incubated in 5 ml of LB medium for 4 h at 37 °C to measure formazan production.

#### **Elastase and pyocyanin assay**

Elastase activity was measured as previously described (43). First, 500  $\mu$ l of supernatant from cultures incubated with 50  $\mu$ M or 150  $\mu$ M of the compounds for 4 h or 8 h was mixed with 1 ml of 30 mM Tris-HCl buffer containing 10 mg/ml of Elastin-Congo Red (Sigma-Aldrich). The mixture was then incubated with shaking at 37 °C for 1 to 2 h. After the incubation, 1 ml of the mixture was transferred into a micro tube, which was centrifuged at 13,000 rpm for 1 min. In the pyocyanin assay, 5 ml of supernatants from the cultures incubated for 8 h with 150  $\mu$ M Dkstatin compounds was harvested by centrifugation at 3000 rpm for 20 min. They were then filter-sterilized (0.2- $\mu$ m pore size, Sartorius Minisart Sterile EO filters; Sartorius AG). Then, 4 ml of chloroform was added to 8 ml of the supernatants in a 15 ml conical tube, and the mixture was

homogenized. After homogenization, the tubes were centrifuged at 3000 rpm for 10 min to collect the blue layer fraction submerged to the bottom of the tube. Then, 4 ml of the collected blue layer was transferred into a new tube, and 2 ml of 0.2 N HCl was added to produce a red-colored mixture. For the assay, 1 ml of the mixture was then transferred into a microtube for centrifugation at 13,000 rpm for 1 min. Absorbance at 520 nm (OD<sub>520</sub>) was then measured for the samples.

#### **Autoinducer assay**

In HSL measurements, both C4-HSL and 3-oxo-C12-HSL were extracted from 5 ml of culture supernatants using the equivalent volume of acidified ethyl acetate. The extractions were repeated twice to fully collect the ethyl acetate fraction. N<sub>2</sub> gas was used to evaporate and dry out the collected ethyl acetate fraction. The residues were dissolved in 250  $\mu$ l of HPLC grade ethyl acetate to obtain 20-fold concentrated extracts. Measurement of 3-oxo-C12-HSL was performed using an *E. coli* strain harboring reporter plasmid pKDT17 containing a copy of *lasR-lacZ* transcriptional fusion (44). Samples were 100-fold diluted to culture a volume of reporter strain, and they were then tested to measure  $\beta$ -galactosidase activity. The Miller Units from samples were calculated as described previously (13). The measurement of C4-HSL was conducted through violacein productions of the *Chromobacterium violaceum* CV026 strain (45). The CV026 strain was incubated in 5 ml of LB and LB supplemented with 100-fold diluted extract. After incubation, cell pellets in 1 ml of culture were harvested by centrifugation at 13,000 rpm for 3 min. The pellets were then resuspended using HPLC grade DMSO to dissolve violacein. Violacein was measured at 575 nm absorbance and normalized using the OD<sub>600</sub> value of CV026.

#### **DNA manipulation**

Primer sequences used in the study are listed in Table S2. Plasmid preparation was performed using a Plasmid mini extraction kit (Bioneer Inc). Restriction enzyme digestion, ligation, and agarose gel electrophoresis were performed by following standard methods. A Gibson assembly kit (New England Biolabs Inc) was used in cloning to produce the *dksA1*-fused 3XFLAG strain. Transformation of *E. coli* was carried out by electroporation. Competent *E. coli* cells for electroporation were prepared by repeated washing with 300 mM sucrose. Electroporation settings were 2.5 kV, 25  $\mu$ F, and 200  $\Omega$  for a 2 mm electroporation cuvette. The oligonucleotide primers synthesis and sequencing DNA were performed by Macrogen.

#### **Antibiotic susceptibility test**

Overnight cultured PAO1 was inoculated to 100-fold dilution in 2 ml of LB supplemented with gentamicin, imipenem, streptomycin, tetracycline, kanamycin, and tobramycin ranging from 1  $\mu$ g/ml to 25  $\mu$ g/ml and 150  $\mu$ M of Dkstatin-1 or Dkstatin-2. The incubation took 6 h at 37

## Dkstatin-induced virulence attenuation of *P. aeruginosa*

°C with vigorous shaking. Then, respective incubated samples were serially diluted by tenfold in 1 ml of PBS, and 10 µl of each dilute was spotted onto an LB agar plate for CFU counts. The plates were incubated overnight at 37 °C without shaking.

### Western blot and immunoprecipitation

PAO1 *dksA1::3xFLAG* strain was grown in 20 ml of LB medium supplemented with or without 150 µM of Dkstatin-1 and Dkstatin-2 for 6 to 8 h. Whole cells were pelleted by centrifugation at 3000 rpm for 30 min at 4 °C and were resuspended with 600 to 800 µl of lysis buffer (50 mM Tris-HCl pH 7.5, 75 mM NaCl, 10 mM MgCl<sub>2</sub>, 10% glycerol, 1 mM EDTA, 1 mM PMSF, and 0.01% Triton X-100) with 8 µl of SIGMA FAST protease inhibitor cocktail (Sigma-Aldrich). The pellets were then sonicated at 30% amplitude for 10 s with 10 s intervals on ice and were then centrifuged for 30 min at 4 °C and 14,000 rpm. The supernatants of the lysates were collected and placed into new tubes. Their volumes were adjusted to contain equal quantities of total proteins. Then, 10 to 800 µl of the adjusted samples was used for western blots and immunoprecipitation. For *DksA1::3xFLAG* blotting, 10 µl of samples was loaded on 12% SDS-PAGE and transferred to Amersham Protran premium 0.2 µm nitrocellulose membranes (GE Healthcare Life Sciences) for 1 h in an ice-cold transfer buffer (25 mM Tris, 192 mM glycine pH 8.3 20% methanol (v/v)). Membranes were blocked with a 5% BSA containing TBST solution overnight at 4 °C on a rocking shaker. Blots were incubated with anti-FLAG (Sigma-Aldrich) and anti-rabbit secondary antibodies (Thermo-fisher) and revealed by chemiluminescence. All washes were performed with a TBST solution without BSA. Immunoprecipitation was conducted using ~800 µl of samples with 25 µl of M2 Anti-FLAG magnetic beads (Sigma-Aldrich) after incubating overnight at 4 °C on a rocking shaker. Beads were pelleted using a magnet and were washed once with the lysis buffer. Samples bound to the beads were eluted in 30 µl of lysis buffer by heating at 100 °C for 10 min. The eluted samples were then loaded on 10% SDS-PAGE and blotted by anti-FLAG Ab (Sigma) or anti-*E.coli* RpoB Ab (Abcam).

### RNASeq analysis

To extract total RNA, *P. aeruginosa* PAO1 was incubated for 2 h in 5 ml of LB with vigorous shaking at 37 °C. Then, additional incubation was conducted for 1 h under the same condition with 150 µM of Dkstatin-1 or Dkstatin-2 supplement. Total RNA samples were extracted using an RNeasy mini kit (Qiagen), and total DNA was eliminated using RNase-free DNase set (Qiagen) following the manufacturer's instructions. The extraction was performed as an experimental duplicate. Transcriptome profile comparison and processing the expression data were provided by Ebiogen. RNA quality was assessed by an Agilent 2100 bioanalyzer using the RNA 6000 Nano Chip (Agilent Technologies), and RNA quantification was performed using an ND-2000 Spectrophotometer

(Thermo Inc). For control and testing RNAs, rRNA was removed using a Ribo-Zero Magnetic kit (Epicentre Inc) from each 5 µg of total RNA. The construction of a library was performed using a SMARTer Stranded RNA-Seq Kit (Clontech Lab Inc) according to the manufacturer's instructions. The rRNA-depleted RNAs were used for the cDNA synthesis and shearing, following manufacturer's instructions. Indexing was performed using the Illumina indexes 1 to 12. The enrichment step was carried out using PCR. Subsequently, libraries were checked using the Agilent 2100 bioanalyzer (DNA High Sensitivity Kit) to evaluate the mean fragment size. Quantification was performed using the library quantification kit using a StepOne Real-Time PCR System (Life Technologies Inc). High-throughput sequencing was performed as paired-end 100 sequencing using HiSeq 2500 (Illumina Inc). Bacterial-Seq reads were mapped using a Bowtie2 software tool to obtain the alignment file. DEGs were determined based on counts from unique and multiple alignments using EdgeR within R (R development Core Team, 2016) using Bioconductor (46). The alignment file also was used for assembling transcripts. The quantile normalization method was used for comparisons between samples. Gene classification was based on searches done by DAVID (<http://david.abcc.ncifcrf.gov/>).

### Mouse infection

Eight-week-old female C57BL/6 mice (Orient) were infected with PAO1 and a combination of Dksatin-1 or Dkstatin-2. PAO1 pellets incubated in LB broth at 37 °C for 6 h were resuspended in 1 ml of sterile phosphate-buffered saline (PBS) containing 1% of DMSO or 150 µM of Dkstatin compounds, and they were adjusted to 10<sup>6</sup> cells per 20 µl as an initial infection dose. Mice were anesthetized by injection of 20% (v/v) ketamine and 8% (v/v) Rompun mixed in saline. During anesthetization, 20 µl of prepared bacterial cells was inhaled directly through the nose by a pipette as previously described (47). The survival of the mice was monitored for 48 h with 2 h intervals. The survival of the mice was expressed as a Kaplan–Meier curve using Graph Pad Prism software ([www.graphpad.com](http://www.graphpad.com)). To measure the bacterial load in the lungs, another set of mice (n = 4) were infected with the same administration above. All mice were euthanized in a CO<sub>2</sub> gas chamber 12 h post infection. Then, whole lungs from mice in each group were immediately collected and homogenized for serial dilution in 1 ml of PBS. For histological observation, lungs were perfused with sterile PBS and staining with hematoxylin and eosin was conducted following a standard protocol (48).

### Statistical analysis

Statistical analysis of the data in the experiments was carried out by statistic tools within Graph Pad Prism software ([www.graphpad.com](http://www.graphpad.com)) for the paired Student's *t*-test. A *p*-value of less than 0.05 was considered statistically significant. All experiments were repeated for reproducibility.

## Data availability

Raw data files in RNAseq analysis are available to access in GEO database (GEO accession: GSE163248).

**Supporting information**—This article contains supporting information (30).

**Acknowledgments**—This work was supported by grants from the National Research Foundation (NRF) of Korea, (2017M3A9F3041233, 2019R1A6A1A03032869). This research was also supported by a grant from the Korea Health Technology R&D Project, funded by the Ministry of Health & Welfare, Korea (HI14C1324). This work was also supported by Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries (IPET) through Agricultural Microbiome R&D Program, funded by Ministry of Agriculture, Food and Rural Affairs (MAFRA) (918003041SB010).

The chemical library used in this study was kindly provided by Korea Chemical Bank ([www.chembank.org](http://www.chembank.org)) of Korea Research Institute of Chemical Technology.

**Author contributions**—K. B. M. and S. S. Y. conceptualized and designed the experiments. K. B. M., W. H., K. -M. L., J. B. K., and S. S. Y. performed the experiments and analyzed the experimental results. K. B. M., J. B. K., and S. S. Y. drafted the article.

**Conflict of interest**—We declare that there are no conflicts of interest with the contents of this article.

**Abbreviations**—The abbreviations used are: CF, cystic fibrosis; DEG, differentially expressed gene; GM, gentamycin; GO, gene ontology; HSL, homoserine lactone; Imp, imipenem; KM, kanamycin; MCS, multicloning site; NIR, nitrite reductase; NOR, nitric oxide reductase; QS, quorum sensing; SM, streptomycin; TB, tobramycin; TC, tetracycline.

## References

- Moradali, M. F., Ghods, S., and Rehm, B. H. (2017) *Pseudomonas aeruginosa* lifestyle: A paradigm for adaptation, survival, and persistence. *Front. Cell. Infect. Microbiol.* **7**, 39
- Valentini, M., Gonzalez, D., Mavridou, D. A., and Filloux, A. (2018) Lifestyle transitions and adaptive pathogenesis of *Pseudomonas aeruginosa*. *Curr. Opin. Microbiol.* **41**, 15–20
- Gourse, R. L., Chen, A. Y., Gopalkrishnan, S., Sanchez-Vazquez, P., Myers, A., and Ross, W. (2018) Transcriptional responses to ppGpp and DksA. *Annu. Rev. Microbiol.* **72**, 163–184
- Ross, W., Sanchez-Vazquez, P., Chen, A. Y., Lee, J. H., Burgos, H. L., and Gourse, R. L. (2016) ppGpp binding to a site at the RNAP-DksA interface accounts for its dramatic effects on transcription initiation during the stringent response. *Mol. Cell* **62**, 811–823
- Doniselli, N., Rodriguez-Aliaga, P., Amidani, D., Bardales, J. A., Bustamante, C., Guerra, D. G., and Rivetti, C. (2015) New insights into the regulatory mechanisms of ppGpp and DksA on *Escherichia coli* RNA polymerase-promoter complex. *Nucleic Acids Res.* **43**, 5249–5262
- Paul, B. J., Barker, M. M., Ross, W., Schneider, D. A., Webb, C., Foster, J. W., and Gourse, R. L. (2004) DksA: A critical component of the transcription initiation machinery that potentiates the regulation of rRNA promoters by ppGpp and the initiating NTP. *Cell* **118**, 311–322
- Perederina, A., Svetlov, V., Vassilyeva, M. N., Tahirov, T. H., Yokoyama, S., Artsimovitch, I., and Vassylyev, D. G. (2004) Regulation through the secondary channel—structural framework for ppGpp-DksA synergism during transcription. *Cell* **118**, 297–309
- Bernardo, L. M., Johansson, L. U., Solera, D., Skarfstad, E., and Shingler, V. (2006) The guanosine tetraphosphate (ppGpp) alarmone, DksA and promoter affinity for RNA polymerase in regulation of sigma-dependent transcription. *Mol. Microbiol.* **60**, 749–764
- Kolmsee, T., Delic, D., Agyenim, T., Calles, C., and Wagner, R. (2011) Differential stringent control of *Escherichia coli* rRNA promoters: Effects of ppGpp, DksA and the initiating nucleotides. *Microbiology (Reading)* **157**, 2871–2879
- Dalebroux, Z. D., Svensson, S. L., Gaynor, E. C., and Swanson, M. S. (2010) ppGpp conjures bacterial virulence. *Microbiol. Mol. Biol. Rev.* **74**, 171–199
- Parshin, A., Shiver, A. L., Lee, J., Ozerova, M., Schneidman-Duhovny, D., Gross, C. A., and Borukhov, S. (2015) DksA regulates RNA polymerase in *Escherichia coli* through a network of interactions in the secondary channel that includes sequence insertion 1. *Proc. Natl. Acad. Sci. U. S. A.* **112**, E6862–E6871
- Perron, K., Comte, R., and van Delden, C. (2005) DksA represses ribosomal gene transcription in *Pseudomonas aeruginosa* by interacting with RNA polymerase on ribosomal promoters. *Mol. Microbiol.* **56**, 1087–1102
- Min, K. B., and Yoon, S. S. (2020) Transcriptome analysis reveals that the RNA polymerase-binding protein DksA1 has pleiotropic functions in *Pseudomonas aeruginosa*. *J. Biol. Chem.* **295**, 3851–3864
- Gray, M. J. (2019) Inorganic polyphosphate accumulation in *Escherichia coli* is regulated by DksA but not by (p)ppGpp. *J. Bacteriol.* **201**, e00664–18
- Magnusson, L. U., Gummesson, B., Joksimovic, P., Farewell, A., and Nystrom, T. (2007) Identical, independent, and opposing roles of ppGpp and DksA in *Escherichia coli*. *J. Bacteriol.* **189**, 5193–5202
- Pal, R. R., Bag, S., Dasgupta, S., Das, B., and Bhadra, R. K. (2012) Functional characterization of the stringent response regulatory gene dksA of *Vibrio cholerae* and its role in modulation of virulence phenotypes. *J. Bacteriol.* **194**, 5638–5648
- Azriel, S., Goren, A., Rahav, G., and Gal-Mor, O. (2016) The stringent response regulator DksA is required for *Salmonella enterica* Serovar Typhimurium growth in minimal medium, motility, biofilm formation, and intestinal colonization. *Infect. Immun.* **84**, 375–384
- Henard, C. A., Bourret, T. J., Song, M., and Vazquez-Torres, A. (2010) Control of redox balance by the stringent response regulatory protein promotes antioxidant defenses of *Salmonella*. *J. Biol. Chem.* **285**, 36785–36793
- Blaby-Haas, C. E., Furman, R., Rodionov, D. A., Artsimovitch, I., and de Crecy-Lagard, V. (2011) Role of a Zn-independent DksA in Zn homeostasis and stringent response. *Mol. Microbiol.* **79**, 700–715
- Scoffone, V. C., Trespido, G., Chiarelli, L. R., Barbieri, G., and Buroni, S. (2019) Quorum sensing as antivirulence target in cystic fibrosis pathogens. *Int. J. Mol. Sci.* **20**, 1838
- Stockert, J. C., Horobin, R. W., Colombo, L. L., and Blazquez-Castro, A. (2018) Tetrazolium salts and formazan products in cell biology: Viability assessment, fluorescence imaging, and labeling perspectives. *Acta Histochem.* **120**, 159–167
- Jiang, Q., Chen, J., Yang, C., Yin, Y., and Yao, K. (2019) Quorum sensing: A prospective therapeutic target for bacterial diseases. *Biomed. Res. Int.* **2019**, 2015978
- Lee, J., and Zhang, L. (2015) The hierarchy quorum sensing network in *Pseudomonas aeruginosa*. *Protein Cell* **6**, 26–41
- Lee, K. M., Yoon, M. Y., Park, Y., Lee, J. H., and Yoon, S. S. (2011) Anaerobiosis-induced loss of cytotoxicity is due to inactivation of quorum sensing in *Pseudomonas aeruginosa*. *Infect. Immun.* **79**, 2792–2800
- Nathwani, D., Raman, G., Sulham, K., Gavaghan, M., and Menon, V. (2014) Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant *Pseudomonas aeruginosa* infections: A systematic review and meta-analysis. *Antimicrob. Resist. Infect. Control* **3**, 32
- Yoon, S. S., Hennigan, R. F., Hilliard, G. M., Ochsner, U. A., Parvatiyar, K., Kamani, M. C., Allen, H. L., DeKievit, T. R., Gardner, P. R., Schwab, U., Rowe, J. J., Iglewski, B. H., McDermott, T. R., Mason, R. P., Wozniak, D. J., et al. (2002) *Pseudomonas aeruginosa* anaerobic respiration in biofilms: Relationships to cystic fibrosis pathogenesis. *Dev. Cell* **3**, 593–603

## Dkstatin-induced virulence attenuation of *P. aeruginosa*

27. Arai, H. (2011) Regulation and function of versatile aerobic and anaerobic respiratory metabolism in *Pseudomonas aeruginosa*. *Front. Microbiol.* **2**, 103
28. Hirai, T., Osamura, T., Ishii, M., and Arai, H. (2016) Expression of multiple *cbb3* cytochrome c oxidase isoforms by combinations of multiple isosubunits in *Pseudomonas aeruginosa*. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 12815–12819
29. Ekici, S., Yang, H., Koch, H. G., and Daldal, F. (2012) Novel transporter required for biogenesis of *cbb3*-type cytochrome c oxidase in *Rhodobacter capsulatus*. *mBio* **3**, e00293-11
30. Choi, K. H., and Schweizer, H. P. (2006) mini-Tn7 insertion in bacteria with single attTn7 sites: Example *Pseudomonas aeruginosa*. *Nat. Protoc.* **1**, 153–161
31. Kim, J. S., Liu, L., Fitzsimmons, L. F., Wang, Y., Crawford, M. A., Mastrogiovanni, M., Trujillo, M., Till, J. K. A., Radi, R., Dai, S., and Vazquez-Torres, A. (2018) DksA-DnaJ redox interactions provide a signal for the activation of bacterial RNA polymerase. *Proc. Natl. Acad. Sci. U. S. A.* **115**, E11780–E11789
32. Berger, R., Resnati, G., Metrangolo, P., Weber, E., and Hulliger, J. (2011) Organic fluorine compounds: A great opportunity for enhanced materials properties. *Chem. Soc. Rev.* **40**, 3496–3508
33. Ikeda, H., Yukawa, M., and Niiya, T. (2006) *Ab initio* molecular orbital study of the reactivity of active alkyl groups. VII. Solvent effects on the formation of enolate isomers from 2-butanone with methoxide anion in methanol. *Chem. Pharm. Bull. (Tokyo)* **54**, 731–734
34. Cloutier, J. F., Drouin, R., Weinfeld, M., O'Connor, T. R., and Castonguay, A. (2001) Characterization and mapping of DNA damage induced by reactive metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) at nucleotide resolution in human genomic DNA. *J. Mol. Biol.* **313**, 539–557
35. Kim, H. Y., Go, J., Lee, K. M., Oh, Y. T., and Yoon, S. S. (2018) Guanosine tetra- and pentaphosphate increase antibiotic tolerance by reducing reactive oxygen species production in *Vibrio cholerae*. *J. Biol. Chem.* **293**, 5679–5694
36. Klockgether, J., and Tummler, B. (2017) Recent advances in understanding *Pseudomonas aeruginosa* as a pathogen. *F1000Res.* **6**, 1261
37. Paczkowski, J. E., Mukherjee, S., McCready, A. R., Cong, J. P., Aquino, C. J., Kim, H., Henke, B. R., Smith, C. D., and Bassler, B. L. (2017) Flavonoids suppress *Pseudomonas aeruginosa* virulence through allosteric inhibition of quorum-sensing receptors. *J. Biol. Chem.* **292**, 4064–4076
38. Yang, Y. X., Xu, Z. H., Zhang, Y. Q., Tian, J., Weng, L. X., and Wang, L. H. (2012) A new quorum-sensing inhibitor attenuates virulence and decreases antibiotic resistance in *Pseudomonas aeruginosa*. *J. Microbiol.* **50**, 987–993
39. Fan, X., Liang, M., Wang, L., Chen, R., Li, H., and Liu, X. (2017) Aii810, a novel cold-adapted N-acylhomoserine lactonase discovered in a meta-genome, can strongly attenuate *Pseudomonas aeruginosa* virulence factors and biofilm formation. *Front. Microbiol.* **8**, 1950
40. Guendouze, A., Plener, L., Bzdrenga, J., Jacquet, P., Remy, B., Elias, M., Lavigne, J. P., Daude, D., and Chabriere, E. (2017) Effect of quorum quenching lactonase in clinical isolates of *Pseudomonas aeruginosa* and comparison with quorum sensing inhibitors. *Front. Microbiol.* **8**, 227
41. O'Loughlin, C. T., Miller, L. C., Siryaporn, A., Drescher, K., Semmelhack, M. F., and Bassler, B. L. (2013) A quorum-sensing inhibitor blocks *Pseudomonas aeruginosa* virulence and biofilm formation. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 17981–17986
42. Geske, G. D., O'Neill, J. C., Miller, D. M., Mattmann, M. E., and Blackwell, H. E. (2007) Modulation of bacterial quorum sensing with synthetic ligands: Systematic evaluation of N-acylated homoserine lactones in multiple species and new insights into their mechanisms of action. *J. Am. Chem. Soc.* **129**, 13613–13625
43. Pearson, J. P., Pesci, E. C., and Iglewski, B. H. (1997) Roles of *Pseudomonas aeruginosa* las and rhl quorum-sensing systems in control of elastase and rhamnolipid biosynthesis genes. *J. Bacteriol.* **179**, 5756–5767
44. Pearson, J. P., Gray, K. M., Passador, L., Tucker, K. D., Eberhard, A., Iglewski, B. H., and Greenberg, E. P. (1994) Structure of the autoinducer required for expression of *Pseudomonas aeruginosa* virulence genes. *Proc. Natl. Acad. Sci. U. S. A.* **91**, 197–201
45. Steindler, L., and Venturi, V. (2007) Detection of quorum-sensing N-acyl homoserine lactone signal molecules by bacterial biosensors. *FEMS Microbiol. Lett.* **266**, 1–9
46. Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., Hornik, K., Hothorn, T., Huber, W., Iacus, S., Irizarry, R., et al. (2004) Bioconductor: Open software development for computational biology and bioinformatics. *Genome Biol.* **5**, R80
47. Lee, K., Lee, K. M., Go, J., Ryu, J. C., Ryu, J. H., and Yoon, S. S. (2016) The ferrichrome receptor A as a new target for *Pseudomonas aeruginosa* virulence attenuation. *FEMS Microbiol. Lett.* **363**, fnw104
48. Filloux, A., and Ramos, J. L. (2014) Preface. *Pseudomonas* methods and protocols. *Methods Mol. Biol.* **1149**, v